Melanotan II For Promotes Skin Tanning CAS:121062-08-6
Melanotan II (MT-II) has emerged as a synthetic peptide of interest for its ability to induce skin tanning without prolonged UV exposure. Unlike traditional tanning methods, MT-II operates at a molecular level, offering a novel approach to achieving a sun-kissed complexion. This article delves into its structure, mechanisms, applications, and practical considerations, presenting a fresh perspective to avoid redundancy with existing content.
What is Melanotan II?
Origin & Development:
Developed in the 1980s at the University of Arizona, MT-II was initially investigated for its potential to reduce skin cancer risk by stimulating protective melanin. Derived from α-MSH (alpha-melanocyte-stimulating hormone), it was engineered to resist enzymatic degradation, enhancing its longevity.
Chemical Structure:
MT-II's sequence (Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂) includes non-natural amino acids like norleucine (Nle) and D-phenylalanine, boosting receptor affinity and stability.
Mechanism of Action:
MT-II binds to melanocortin receptors (MC1R-MC5R), primarily MC1R in melanocytes. Activation triggers melanogenesis, increasing eumelanin (dark pigment) production. Notably, its cross-reactivity with MC3R and MC4R influences appetite and libido, adding layers to its pharmacological profile.
Distinctive Features
●Dual-Function Peptide: Beyond tanning, MT-II's MC4R activation enhances sexual arousal and suppresses appetite, a unique off-label appeal.
●UV-Independent Tanning: Unlike topical agents requiring UV exposure, MT-II initiates melanin synthesis systemically, though UV exposure intensifies results.
●Rapid Onset: Users report tanning within days, contrasting with weeks needed for natural methods.
●Self-Administration Flexibility: Available as subcutaneous injections or nasal sprays, though bioavailability varies.
●Comparative Edge:
Compared to Melanotan I (longer half-life but less potent), MT-II offers a broader receptor profile, contributing to ancillary effects like fat loss and improved erectile function.
Applications
Cosmetic Use:
●Sunless Tanning: Ideal for individuals with fair skin (Fitzpatrick I-II) struggling to tan naturally.
●Tattoo Enhancement: Darkened pigments in tattoos and moles, a less-discussed aesthetic effect.
Medical Potential:
●Photoprotection: Studies suggest MT-II reduces UV-induced DNA damage, benefiting those with erythropoietic protoporphyria.
●Libido Disorders: Investigated for hypoactive sexual desire disorder due to MC4R activation.
●Obesity Research: Appetite suppression opens avenues for weight management studies.
Research Frontiers:
●Neuroprotection: MC4R's role in neuroinflammation is under exploration.
●Depression Models: Preclinical data hint at mood modulation via melanocortin pathways.
Benefits
●Skin Cancer Mitigation: Eumelanin's antioxidant properties may lower melanoma risk, though unproven in long-term human trials.
●Psychological Well-being: Enhanced self-esteem from tanning, particularly in bodybuilders and aesthetic-focused communities.
●Metabolic Advantages: Appetite reduction aids in caloric restriction, synergizing with fitness goals.
User Testimonials:
Anecdotal reports highlight improved confidence and reduced sunburn frequency, though these lack clinical validation.
Dosage Guidelines
Initial Protocol:
●Loading Phase: 0.25–0.5 mg daily via injection for 10–14 days, titrating upward to minimize nausea.
●Maintenance: 1–2 mg weekly. Nasal sprays (0.5–1 mg daily) require higher doses due to lower absorption.
Considerations:
●Titration Strategy: Start low (0.25 mg) to assess tolerance.
●UV Synergy: Brief sun exposure (10–15 minutes) post-dose enhances melanocyte activation.
Risks: Hyperpigmentation, nevi darkening, and rare cases of melanoma progression in predisposed individuals.
Cycle Management
Typical Cycle:
●Duration: 30–60 days, followed by a 4-week washout to prevent receptor desensitization.
●Post-Cycle: Monitor pigment retention; some users maintain tanning with monthly doses.
Adaptive Strategies:
●Pulse Dosing: 2–3 doses weekly post-loading phase to sustain effects.
●Combination Therapy: Stacked with PT-141 (Bremelanotide) for enhanced libido effects.
Half-Life & Pharmacokinetics
●Half-Life: ~2.3 hours, necessitating frequent dosing.
●Metabolism: Hepatic clearance via peptidases, with renal excretion of metabolites.
●Peak Activity: 1–2 hours post-injection, aligning melanogenesis with UV exposure timing.
Pharmacokinetics, Toxicity, and Contraindications (PTC)
Toxicity Profile:
●Acute Effects: Nausea, flushing, and spontaneous erections (priapism risk in males).
●Chronic Risks: Melanocytic hyperplasia, potential for undiagnosed melanoma progression.
Contraindications:
●Medical History: Skin cancer, cardiovascular disease, or psychiatric disorders.
●Drug Interactions: Serotonergic agents (risk of serotonin syndrome via MC4R pathways).
Safety Monitoring:
●Dermatological exams for new or changing moles.
●Blood pressure checks due to vasodilatory effects.
Clinical Data
|
Trade names |
Melanotan II Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 |
|
CAS |
121062-08-6 |
|
Molar mass |
1024.180 |
|
MF |
C50H69N15O9 |
|
Purity |
Above 98% |
|
Apprarance |
10mg/vial,Lyophilized powder |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-19128233885
Conclusion
Melanotan II represents a fascinating intersection of cosmetic desire and biochemical innovation. While its tanning efficacy is undeniable, its unregulated status demands cautious use. Future research may legitimize its medical applications, but current users must navigate its benefits and risks judiciously. As science evolves, MT-II could redefine preventive dermatology and metabolic therapy, provided safety and ethical concerns are addressed.
Hot Tags: melanotan ii for promotes skin tanning cas:121062-08-6, China melanotan ii for promotes skin tanning cas:121062-08-6 manufacturers, suppliers, factory
